THARIMMUNE INC (THAR) Stock News

NASDAQ:THAR - Nasdaq - US4327053090 - Common Stock - Currency: USD

1.36 +0.02 (+1.49%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

THAR Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - ACCESS Newswire

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

a month ago - ACCESS Newswire

Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

2 months ago - Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session

Mentions: HBIO MYGN RIGL CPIX ...

2 months ago - ACCESS Newswire

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

3 months ago - ACCESS Newswire

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

2 months ago - Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session

Mentions: CVM BLRX IBO BCDA ...

2 months ago - ACCESS Newswire

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

2 months ago - ACCESS Newswire

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

2 months ago - ACCESS Newswire

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

11 months ago - InvestorPlace

THAR Stock Earnings: Tharimmune Reported Results for Q2 2024

Tharimmune just reported results for the second quarter of 2024.

2 months ago - ACCESS Newswire

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

3 months ago - ACCESS Newswire

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

3 months ago - ACCESS Newswire

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

4 months ago - ACCESS Newswire

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

5 months ago - ACCESS Newswire

Tharimmune to Present at the Microcap Conference 2025